Celularity (CELU) News Today → Wall Street legend who predicted 2021 tech crash issues new warning (From Chaikin Analytics) (Ad) Free CELU Stock Alerts $3.31 -0.33 (-9.07%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 9:15 AM | globenewswire.comCelularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T TherapyMay 12 at 8:39 PM | marketbeat.comShort Interest in Celularity Inc. (NASDAQ:CELU) Grows By 51.4%Celularity Inc. (NASDAQ:CELU - Get Free Report) saw a large increase in short interest in April. As of April 30th, there was short interest totalling 595,000 shares, an increase of 51.4% from the April 15th total of 393,100 shares. Approximately 5.6% of the shares of the stock are sold short. Based on an average daily volume of 72,300 shares, the days-to-cover ratio is currently 8.2 days.April 30, 2024 | marketbeat.comCelularity Inc. (NASDAQ:CELU) Short Interest UpdateCelularity Inc. (NASDAQ:CELU - Get Free Report) saw a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 393,100 shares, a decrease of 5.5% from the March 31st total of 415,800 shares. Based on an average daily volume of 98,300 shares, the short-interest ratio is presently 4.0 days. Approximately 3.7% of the shares of the stock are sold short.April 22, 2024 | globenewswire.comCelularity Inc. to Host Investor and Analyst Research & Development DayApril 19, 2024 | globenewswire.comCelularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K FilingApril 18, 2024 | globenewswire.comCelularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024April 15, 2024 | globenewswire.comCelularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial ProductsApril 8, 2024 | globenewswire.comCelularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental CellsMarch 30, 2024 | marketbeat.comCelularity Inc. (NASDAQ:CELU) Short Interest Down 16.8% in MarchCelularity Inc. (NASDAQ:CELU - Get Free Report) was the recipient of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 388,300 shares, a decrease of 16.8% from the February 29th total of 466,600 shares. Based on an average trading volume of 269,900 shares, the short-interest ratio is currently 1.4 days. Approximately 3.7% of the shares of the stock are sold short.March 26, 2024 | finance.yahoo.comCelularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3LMarch 20, 2024 | finanznachrichten.deCelularity Inc.: Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular DystrophyMarch 20, 2024 | markets.businessinsider.comCelularity Announces Submission Of Request For Orphan Drug Designation For PDA-002March 20, 2024 | globenewswire.comCelularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular DystrophyMarch 16, 2024 | finance.yahoo.comCELU Apr 2024 10.000 callMarch 15, 2024 | finance.yahoo.comCELU Mar 2024 7.500 putMarch 14, 2024 | finance.yahoo.comCelularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE SummitMarch 14, 2024 | globenewswire.comCelularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE SummitMarch 12, 2024 | marketbeat.comCelularity Inc. (NASDAQ:CELU) Short Interest Down 87.6% in FebruaryCelularity Inc. (NASDAQ:CELU - Get Free Report) was the recipient of a significant drop in short interest in February. As of February 29th, there was short interest totalling 466,600 shares, a drop of 87.6% from the February 14th total of 3,750,000 shares. Currently, 4.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 264,800 shares, the short-interest ratio is currently 1.8 days.March 12, 2024 | globenewswire.comCelularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World CongressMarch 8, 2024 | edition.cnn.comCelularity Inc. Class AMarch 7, 2024 | globenewswire.comCelularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental CellsFebruary 29, 2024 | marketbeat.comTrading was temporarily halted for "CELU" at 07:02 PM with a stated reason of "News pending."February 24, 2024 | finanznachrichten.deCelularity, Inc.: Celularity Announces 1-for-10 Reverse Stock SplitFebruary 23, 2024 | marketwatch.comStocks to Watch: Intuitive Machines, CelularityFebruary 23, 2024 | markets.businessinsider.comCelularity Announce 1-for-10 Reverse Stock SplitFebruary 23, 2024 | marketwatch.comCelularity to Effect 1-for-10 Reverse Stock SplitFebruary 23, 2024 | globenewswire.comCelularity Announces 1-for-10 Reverse Stock SplitFebruary 22, 2024 | finance.yahoo.comCelularity Inc.'s (NASDAQ:CELU) top owners are public companies with 35% stake, while 35% is held by individual investorsFebruary 14, 2024 | finance.yahoo.comCelularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface DiseaseFebruary 14, 2024 | globenewswire.comCelularity's Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface DiseaseFebruary 6, 2024 | benzinga.comCelularity Stock (NASDAQ:CELU) Dividends: History, Yield and DatesFebruary 1, 2024 | finance.yahoo.comCelularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development PipelineJanuary 25, 2024 | finance.yahoo.comCelularity and Genting Leaders Comments on Closing $21 Million Financing TransactionsJanuary 19, 2024 | finanznachrichten.deCelularity, Inc.: Celularity Releases CEO Letter to ShareholdersJanuary 18, 2024 | marketwatch.comCelularity CEO Says 2023 Revenue to Rise About 23% to 27%January 18, 2024 | finance.yahoo.comCelularity Releases CEO Letter to ShareholdersJanuary 4, 2024 | marketwatch.comCelularity Gets Commercialization Deal For Oral Healthcare ProductsJanuary 4, 2024 | finance.yahoo.comCelularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral HealthcareJanuary 3, 2024 | finanznachrichten.deCelularity, Inc.: Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023January 3, 2024 | marketwatch.comCelularity Expects 4Q Product, Services Sales to Nearly TripleJanuary 3, 2024 | msn.comCelularity announces fourth-quarter full-year 2023 revenue outlookJanuary 3, 2024 | finance.yahoo.comCelularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023December 2, 2023 | finance.yahoo.comCelularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q FilingNovember 27, 2023 | finanznachrichten.deCelularity, Inc.: Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q FilingNovember 24, 2023 | msn.comCelularity announces receipt of Nasdaq notice regarding late Form 10-Q filingNovember 22, 2023 | morningstar.comNorth American Morning Briefing: Stock Futures Muted; Nvidia Slips in Offhours TradingOctober 18, 2023 | finance.yahoo.comCelularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product ClassificationOctober 18, 2023 | finance.yahoo.comCelularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product ClassificationSeptember 7, 2023 | finance.yahoo.comCelularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of DirectorsSeptember 1, 2023 | money.usnews.comCelularity Inc - Ordinary Shares - Class A Get Celularity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter. Email Address This Wall Street stock prediction just went viral (Ad)People around the world follow 50-year Wall Street veteran Marc Chaikin for his surprisingly accurate stock predictions. And he just issued an urgent WARNING for some of the most popular stocks in U.S. history. Watch just the first 5 minutes of his new prediction CELU Media Mentions By Week CELU Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CELU News Sentiment▼0.940.55▲Average Medical News Sentiment CELU News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CELU Articles This Week▼51▲CELU Articles Average Week Get Celularity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: RPHM News Today ANVS News Today IMMX News Today CALC News Today AEON News Today ELDN News Today CKPT News Today KZR News Today EGRX News Today BLRX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CELU) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersGold Set to EXPLODE!Gold Safe ExchangeRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap Sniper Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celularity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
